Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aldeyra Therapeutics (ALDX)
NASDAQ:ALDX
RESEARCH TOOLSreports
Aldeyra Therapeutics (ALDX) Stock Price & Analysis
1,491 Followers
ALDX Stock Chart & Stats
Day’s Range$3.93 - $4.1
52-Week Range― - ―
Previous Close$4.07
Volume329.92K
Average Volume (3M)N/A
Market Cap
$241.82M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 02, 2024EPS Estimate
-$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding59,414,489
10 Day Avg. Volume340,405
30 Day Avg. Volume676,488
Standard Deviation0.26
R-Squared0.09
Alpha0.00925
Financial Highlights & Ratios
Price to Book (P/B)2.07
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)123.80
P/FCF Ratio61.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.50Price Target Upside141.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Aldeyra Therapeutics News
PremiumCompany Announcements
Aldeyra Therapeutics Unveils R&D Progress and Goals
PremiumCompany Announcements
Aldeyra Therapeutics Unveils Reproxalap Development UpdateBulls Say, Bears Say
Bulls Say
Clinical DevelopmentAldeyra's positive clinical study results and plans for a new trial designed to satisfy FDA requirements hint at a promising future for its therapeutic pipeline.
Market PotentialWith a large potential market for ADX-629 targeting the prevalent mild to moderate atopic dermatitis, significant market share gains could be on the horizon.
Strategic PartnershipsThe potential for significant milestone payments and shared profits from a partnership with AbbVie serves as a strong incentive for Aldeyra's stock performance.
Bears Say
Clinical Trial ConcernsThe confounding part of the treatment was driven by a placebo group that got worse in an area of drug development where placebo patients generally get slightly better.
Drug Approval SetbackAldeyra received a CRL for the NDA of reproxalap in the treatment of dry eye disease (DED), which indicated that an additional study is required to demonstrate positive effect in the treatment of ocular symptoms.
Regulatory ChallengesThe FDA wants another trial to demonstrate control of symptoms for Reproxalap in DED, and the company has received a CRL.
---
Ownership Overview
29.51% Insiders
14.41% Mutual Funds
11.18% Other Institutional Investors
44.89% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALDX FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Aldeyra Therapeutics’s market cap?
Currently, no data Available
When is Aldeyra Therapeutics’s upcoming earnings report date?
Aldeyra Therapeutics’s upcoming earnings report date is May 02, 2024 which is 8 days ago.
How were Aldeyra Therapeutics’s earnings last quarter?
Aldeyra Therapeutics released its earnings results on Mar 07, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.111 by $0.031.
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate is -$0.11.
How many shares outstanding does Aldeyra Therapeutics have?
Currently, no data Available
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Aldeyra Therapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.111. Following the earnings report the stock price went up 0.238%.
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Among the largest hedge funds holding Aldeyra Therapeutics’s share is Perceptive Advisors LLC. It holds Aldeyra Therapeutics’s shares valued at 30M.
---
Aldeyra Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.50 (141.12% Upside)
$9.50 (141.12% Upside)
Blogger Sentiment
Bullish
ALDX Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.81%
12-Months-Change
Fundamentals
Return on Equity
-23.94%
Trailing 12-Months
Asset Growth
-16.00%
Trailing 12-Months
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
---
ALDX Company Deck
---
ALDX Earnings Call
Q4 2023
0:00 / 0:00
---
ALDX Stock 12 Month Forecast
Average Price Target
$9.50
▲(141.12% Upside)
Technical Analysis
Best Analysts Covering ALDX
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
+38.39%
reiterated a buy rating 5 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +38.39% per trade.
---